{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:07:41Z","timestamp":1792840061845,"version":"4.5.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"DOI":"10.3389\/fped.2020.00123","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T05:05:57Z","timestamp":1585631157000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":51,"title":["Subclinical Cardiac Dysfunction in Childhood Cancer Survivors on 10-Years Follow-Up Correlates With Cumulative Anthracycline Dose and Is Best Detected by Cardiopulmonary Exercise Testing, Circulating Serum Biomarker, Speckle Tracking Echocardiography, and Tissue Doppler Imaging"],"prefix":"10.3389","volume":"8","author":[{"given":"Cordula Maria","family":"Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"K\u00fchn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Hager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meierhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Oberhoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ewert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/cncr.10833","article-title":"Childhood cancer survival in Europe and the United States","volume":"95","author":"Gatta","year":"2002","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.1997.15.4.1544","article-title":"Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the pediatric oncology group experience","volume":"15","author":"Krischer","year":"1997","journal-title":"J Clin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"134679","DOI":"10.4061\/2011\/134679","article-title":"Cardiovascular effects in childhood cancer survivors treated with anthracyclines","volume":"2011","author":"Franco","year":"2011","journal-title":"Cardiol Res Pract."},{"key":"B6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11936-014-0315-4","article-title":"Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment","volume":"16","author":"Raj","year":"2014","journal-title":"Curr Treat Options Cardiovasc Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ijcard.2013.03.133","article-title":"Cardioncology: state of the heart","volume":"168","author":"Todaro","year":"2013","journal-title":"Int J Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/JCO.2010.33.4730","article-title":"High risk of symptomatic cardiac events in childhood cancer survivors","volume":"30","author":"Van Der Pal","year":"2012","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/archinternmed.2010.233","article-title":"Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study","volume":"170","author":"Van Der Pal","year":"2010","journal-title":"Arch Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/nrcardio.2015.65","article-title":"Cardiotoxicity of anticancer treatments","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat Rev Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1161\/01.CIR.0000093196.59829.DF","article-title":"Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy","volume":"108","author":"Lebrecht","year":"2003","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev."},{"key":"B13","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1016\/S0021-9258(17)35746-0","article-title":"Redox cycling of anthracyclines by cardiac mitochondria. I Anthracycline radical formation by NADH dehydrogenase","volume":"261","author":"Davies","year":"1986","journal-title":"J Biol Chem."},{"key":"B14","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1016\/S0021-9258(17)35747-2","article-title":"Redox cycling of anthracyclines by cardiac mitochondria. II formation of superoxide anion, hydrogen peroxide, and hydroxyl radical","volume":"261","author":"Doroshow","year":"1986","journal-title":"J Biol Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12012-007-0005-5","article-title":"Molecular and cellular mechanisms of anthracycline cardiotoxicity","volume":"7","author":"Chen","year":"2007","journal-title":"Cardiovasc Toxicol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.87.11.4275","article-title":"Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro","volume":"87","author":"Ito","year":"1990","journal-title":"Proc Natl Acad Sci USA."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00280-009-1164-9","article-title":"Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats","volume":"66","author":"Thompson","year":"2010","journal-title":"Cancer Chemother Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1200\/JCO.2007.14.9401","article-title":"Anthracycline cardiotoxicity: from bench to bedside","volume":"26","author":"Gianni","year":"2008","journal-title":"J Clin Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1200\/JCO.2017.76.3920","article-title":"Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention","volume":"36","author":"Armenian","year":"2018","journal-title":"J Clin Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/MOP.0000000000000675","article-title":"Cardiovascular disease in survivors of childhood cancer","volume":"30","author":"Bansal","year":"2018","journal-title":"Curr Opin Pediatr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1017\/S1047951115000906","article-title":"Cardiac complications in childhood cancer survivors treated with anthracyclines","volume":"25","author":"Franco","year":"2015","journal-title":"Cardiol Young."},{"key":"B23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00246-010-9878-3","article-title":"Anthracycline-associated cardiotoxicity in survivors of childhood cancer","volume":"32","author":"Trachtenberg","year":"2011","journal-title":"Pediatr Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12012-007-0006-4","article-title":"Anthracycline cardiotoxicity in long-term survivors of childhood cancer","volume":"7","author":"Scully","year":"2007","journal-title":"Cardiovasc Toxicol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/hrt.2007.136093","article-title":"Anthracycline associated cardiotoxicity in survivors of childhood cancer","volume":"94","author":"Lipshultz","year":"2008","journal-title":"Heart"},{"key":"B26","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1007\/s00431-003-1275-y","article-title":"The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer","volume":"162","author":"Elbl","year":"2003","journal-title":"Eur J Pediatr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/tpj.2015.63","article-title":"Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia","volume":"16","author":"Krajinovic","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","volume":"30","author":"Visscher","year":"2012","journal-title":"J Clin Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/bcp.13008","article-title":"Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity","volume":"82","author":"Aminkeng","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cge.12392","article-title":"The emerging era of pharmacogenomics: current successes, future potential, and challenges","volume":"86","author":"Lee","year":"2014","journal-title":"Clin Genet."},{"key":"B31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/sj.leu.2402046","article-title":"Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group","volume":"15","author":"Creutzig","year":"2001","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1200\/JCO.2015.61.5187","article-title":"Equivalence ratio for daunorubicin to doxorubicin in relation to late heart failure in survivors of childhood cancer","volume":"33","author":"Feijen","year":"2015","journal-title":"J Clin Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nrclinonc.2013.195","article-title":"Treatment-related cardiotoxicity in survivors of childhood cancer","volume":"10","author":"Lipshultz","year":"2013","journal-title":"Nat Rev Clin Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1159\/000360238","article-title":"Cardiotoxicity and cardioprotection in childhood cancer","volume":"132","author":"Lipshultz","year":"2014","journal-title":"Acta Haematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40272-014-0085-1","article-title":"Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers","volume":"16","author":"Lipshultz","year":"2014","journal-title":"Paediatr Drugs"},{"key":"B37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2217\/fca.12.44","article-title":"Cardiotoxicity in childhood cancer survivors: strategies for prevention and management","volume":"8","author":"Harake","year":"2012","journal-title":"Future Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1542\/peds.2007-0575","article-title":"Monitoring for cardiovascular disease in survivors of childhood cancer: report from the cardiovascular disease task force of the children's oncology group","volume":"121","author":"Shankar","year":"2008","journal-title":"Pediatrics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1200\/JCO.2017.77.0180","article-title":"Surveillance for late effects in childhood cancer survivors","volume":"36","author":"Landier","year":"2018","journal-title":"J Clin Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"672","DOI":"10.7326\/M13-2498","article-title":"Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure","volume":"160","author":"Wong","year":"2014","journal-title":"Ann Intern Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/annonc\/mdf167","article-title":"Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review","volume":"13","author":"Kremer","year":"2002","journal-title":"Ann Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0894-7317(88)80062-2","article-title":"Echocardiographic and doppler assessment of hypertrophic cardiomyopathy","volume":"1","author":"Rakowski","year":"1988","journal-title":"J Am Soc Echocardiogr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the european society of cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/ejcts\/ezx369","article-title":"Clinical long-term outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in infants","volume":"53","author":"Schleihauf","year":"2018","journal-title":"Eur J Cardiothorac Surg."},{"key":"B45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1164\/rccm.167.2.211","article-title":"ATS\/ACCP statement on cardiopulmonary exercise testing","volume":"167","author":"American Thoracic","year":"2003","journal-title":"Am J Respir Crit Care Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","article-title":"Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography","volume":"16","author":"Zoghbi","year":"2003","journal-title":"J Am Soc Echocardiogr."},{"key":"B47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1067\/mje.2002.116532","article-title":"Quantification of regional left and right ventricular radial and longitudinal function in healthy children using ultrasound-based strain rate and strain imaging","volume":"15","author":"Weidemann","year":"2002","journal-title":"J Am Soc Echocardiogr."},{"key":"B48","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ijcard.2011.11.033","article-title":"Tricuspid valve surgery improves cardiac output and exercise performance in patients with Ebstein's anomaly","volume":"166","author":"Kuhn","year":"2013","journal-title":"Int J Cardiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.echo.2008.02.006","article-title":"Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study","volume":"21","author":"Pettersen","year":"2008","journal-title":"J Am Soc Echocardiogr."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/0735-1097(95)00390-8","article-title":"Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients","volume":"26","author":"Klues","year":"1995","journal-title":"J Am Coll Cardiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jcmg.2015.02.014","article-title":"Ethnic-specific normative reference values for echocardiographic LA and LV Size, LV mass, and systolic function: the EchoNoRMAL study","volume":"8","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"B52","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1161\/CIRCIMAGING.109.926022","article-title":"Reference values and distribution of conventional echocardiographic Doppler measures and longitudinal tissue Doppler velocities in a population free from cardiovascular disease","volume":"3","author":"Dalen","year":"2010","journal-title":"Circ Cardiovasc Imaging"},{"key":"B53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.echo.2012.10.008","article-title":"Normal ranges of left ventricular strain: a meta-analysis","volume":"26","author":"Yingchoncharoen","year":"2013","journal-title":"J Am Soc Echocardiogr."},{"key":"B54","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jcmg.2014.06.013","article-title":"Practical guidance in echocardiographic assessment of global longitudinal strain","volume":"8","author":"Negishi","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"B55","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.hlc.2014.10.003","article-title":"Tissue Doppler imaging in echocardiography: value and limitations","volume":"24","author":"Kadappu","year":"2015","journal-title":"Heart Lung Circ."},{"key":"B56","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/mrm.10051","article-title":"Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement","volume":"47","author":"Kellman","year":"2002","journal-title":"Magn Reson Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mrm.20110","article-title":"Modified look-locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart","volume":"52","author":"Messroghli","year":"2004","journal-title":"Magn Reson Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1532-429X-14-63","article-title":"Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method","volume":"14","author":"Kellman","year":"2012","journal-title":"J Cardiovasc Magn Reson."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1002\/cncr.11274","article-title":"Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study","volume":"97","author":"Sorensen","year":"2003","journal-title":"Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2001.19.1.191","article-title":"Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study","volume":"19","author":"Kremer","year":"2001","journal-title":"J Clin Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1200\/JCO.1998.16.2.545","article-title":"Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia","volume":"16","author":"Nysom","year":"1998","journal-title":"J Clin Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the international late effects of childhood cancer guideline harmonization group","volume":"16","author":"Armenian","year":"2015","journal-title":"Lancet Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/pbc.24410","article-title":"Exercise capacity in long-term survivors of pediatric cancer: an analysis from the cardiac risk factors in childhood cancer survivors study","volume":"60","author":"Miller","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/pbc.22606","article-title":"Subclinical cardiac dysfunction and exercise performance in childhood cancer survivors","volume":"56","author":"De Caro","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/pbc.21289","article-title":"Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia","volume":"49","author":"Jarfelt","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/pbc.25492","article-title":"Impaired exercise capacity and left ventricular function in long-term adult survivors of childhood acute lymphoblastic leukemia","volume":"62","author":"Christiansen","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1200\/JCO.2010.30.3404","article-title":"Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes","volume":"30","author":"Lipshultz","year":"2012","journal-title":"J Clin Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1161\/01.CIR.102.11.1216","article-title":"It's time for a change to a troponin standard","volume":"102","author":"Jaffe","year":"2000","journal-title":"Circulation"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.amjcard.2007.11.012","article-title":"Biology of the natriuretic peptides","volume":"101","author":"Martinez-Rumayor","year":"2008","journal-title":"Am J Cardiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMoa031994","article-title":"Plasma natriuretic peptide levels and the risk of cardiovascular events and death","volume":"350","author":"Wang","year":"2004","journal-title":"N Engl J Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.amjcard.2008.04.048","article-title":"Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction","volume":"102","author":"Grewal","year":"2008","journal-title":"Am J Cardiol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","article-title":"Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia","volume":"23","author":"Lipshultz","year":"2005","journal-title":"J Clin Oncol."},{"key":"B75","first-page":"1789","article-title":"Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis","volume":"60","author":"Arola","year":"2000","journal-title":"Cancer Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cbi.2008.09.012","article-title":"Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: role for heme oxygenase-1 down-modulation","volume":"177","author":"Bernuzzi","year":"2009","journal-title":"Chem Biol Interact."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.106.174287","article-title":"Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention","volume":"113","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"B78","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.carpath.2009.07.004","article-title":"Pathology of late-onset anthracycline cardiomyopathy","volume":"19","author":"Bernaba","year":"2010","journal-title":"Cardiovasc Pathol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1532-429X-10-5","article-title":"Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy","volume":"10","author":"Fallah-Rad","year":"2008","journal-title":"J Cardiovasc Magn Reson."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","article-title":"The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.amjcard.2010.09.048","article-title":"Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy","volume":"107","author":"Tsai","year":"2011","journal-title":"Am J Cardiol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/j.1540-8175.2008.00695.x","article-title":"Evaluation of the left ventricular function with tissue tracking and tissue Doppler echocardiography in pediatric malignancy survivors after anthracycline therapy","volume":"25","author":"Karakurt","year":"2008","journal-title":"Echocardiography"},{"key":"B83","doi-asserted-by":"publisher","first-page":"SC01","DOI":"10.7860\/JCDR\/2016\/19652.8249","article-title":"Tissue Doppler imaging and focal, late-onset anthracycline-induced cardiovascular disease in long term survivors of childhood cancer: a research article","volume":"10","author":"Rajapreyar","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/JCO.2006.09.7451","article-title":"Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors","volume":"25","author":"Hudson","year":"2007","journal-title":"J Clin Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.echo.2007.04.007","article-title":"Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients","volume":"20","author":"Ganame","year":"2007","journal-title":"J Am Soc Echocardiogr."},{"key":"B86","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/00148581-200507020-00001","article-title":"Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management","volume":"7","author":"Iarussi","year":"2005","journal-title":"Paediatr Drugs"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S0301-5629(00)00252-0","article-title":"Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines","volume":"26","author":"Kapusta","year":"2000","journal-title":"Ultrasound Med Biol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJM199103213241205","article-title":"Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood","volume":"324","author":"Lipshultz","year":"1991","journal-title":"N Engl J Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/bcp.13120","article-title":"Prevention of cardiotoxicity among survivors of childhood cancer","volume":"83","author":"Hutchins","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/pbc.20358","article-title":"Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients","volume":"44","author":"Anderson","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1089\/ars.2012.4877","article-title":"Iron chelators with topoisomerase-inhibitory activity and their anticancer applications","volume":"18","author":"Rao","year":"2013","journal-title":"Antioxid Redox Signal."},{"key":"B92","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1089\/ars.2012.4795","article-title":"Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection","volume":"18","author":"Sterba","year":"2013","journal-title":"Antioxid Redox Signal."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12872-016-0364-6","article-title":"Rationale and design of the children's oncology group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure","volume":"16","author":"Armenian","year":"2016","journal-title":"BMC Cardiovasc Disord."},{"key":"B95","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1200\/JCO.2002.12.102","article-title":"Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer","volume":"20","author":"Lipshultz","year":"2002","journal-title":"J Clin Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/978-3-642-74643-7_103","article-title":"Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial","volume":"33","author":"Kraft","year":"1990","journal-title":"Haematol Blood Transfus."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fped.2020.00123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T18:11:32Z","timestamp":1615054292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fped.2020.00123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":96,"alternative-id":["10.3389\/fped.2020.00123"],"URL":"https:\/\/doi.org\/10.3389\/fped.2020.00123","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]},"article-number":"123"}}